Want to see BNTC full AI Analyst Report?
Benitec Biopharma (BNTC) Hedge Fund Trading Activity
Trend: ▲ Hedge Funds Increased Holdings by 212.1K Shares Last Quarter
Hedge Fund Holdings in BNTC
Based on the 13F filings of 489 Hedge Funds tracked by TipRanks, as submitted to the SEC.
Hedge Fund Confidence Signal
Hedge Fund Activity
Activity
Star Ranking
| Follow | |||||||
|---|---|---|---|---|---|---|---|
 BlackRock, Inc. | Not Ranked | Added | 18.67% | $18,827,506 | <0.01% | ||
 Peter Kolchinsky | RA Capital Management | Not Changed | 0.00% | $24,753,000 | 0.22% | ||
| Andrew Alkon | EntryPoint Capital, LLC | Reduced | -38.13% | $201,342 | 0.05% |
FAQ
Which hedge funds hold Benitec Biopharma?
The hedge funds that hold the most shares in Benitec Biopharma are Andrew Alkon, Peter Kolchinsky and BlackRock, Inc..
Are hedge funds buying or selling BNTC?
In the last quarter hedge funds have Increased their holdings in Benitec Biopharma by 212.1K shares.
Where can I see a list of the best rated hedge funds?
You can see a list of the best hedge funds here.
Who is the best-performing hedge fund manager?
The top-rated hedge fund managers can be seen here: Top Hedge Fund Managers
Does Warren Buffet hold shares in Benitec Biopharma stock?
Warren Buffet currently does not own shares in Benitec Biopharma.
What is a 13F filing, and how does it help investors?
A 13F form, also known as a "Report of Investment Manager," is a quarterly report that investment advisors registered with the Securities and Exchange Commission (SEC) must file if they manage at least $100 million in assets. The 13F form lists all of the publicly traded securities that the investment advisor owns as of the end of the reporting period. To read more about the 13F, click here
